Charles River Discovery Research Services Germany GmbH

Name of PI: Julia Schueler, DVM, PhD, research director¸

Charles River Discovery Research Services Germany GmbH
Am Flughafen 12-14
79108 Freiburg

Team members working on ITCC-P4 with their position and email address
  • Julia Schueler, DVM, PhD, research director;
  • Eva Oswald, PhD, lab head
  • Anna Edinger, laboratory technician II
  • Dorothee Lenhard, research technician III
  • Melina Lamorte, research technician II
  • Silke Aberle, PhD, research technician II
Company presentation

Charles River is an early-stage contract research organization (CRO). We have developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. At Charles River Freiburg we support our clients with the development of novel anti-cancer drugs using our large and diverse collection of patient-derived xenografts. We are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do. Our work helps to improve the health and well-being of many people across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.